LMR Partners LLP Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY)

LMR Partners LLP reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 37.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 132,167 shares of the biopharmaceutical company’s stock after selling 77,795 shares during the quarter. LMR Partners LLP’s holdings in Bristol-Myers Squibb were worth $7,475,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BMY. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $28,000. Transce3nd LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Westend Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $38,000. Finally, Tacita Capital Inc acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 3.6%

NYSE:BMY opened at $48.12 on Tuesday. The company has a market capitalization of $97.92 billion, a P/E ratio of -10.89, a P/E/G ratio of 2.07 and a beta of 0.39. The stock’s 50 day moving average price is $54.31 and its 200 day moving average price is $56.21. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the prior year, the business earned ($4.40) earnings per share. The company’s revenue was down 5.6% on a year-over-year basis. On average, research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.15%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Jefferies Financial Group decreased their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $58.00.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. The trade was a 2.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.